Sky Labs' CART Monitor Validates Cuffless BP Tracking for AF and Heart Failure Patients
Event summary
- Sky Labs presented clinical data at ESC Congress 2026 demonstrating CART's utility in monitoring AF and heart failure patients.
- CART achieved 80% analyzable data rate in AF patients and met ESH error margin criteria in heart failure patients.
- Device validated against European Society of Hypertension recommendations for cuffless BP monitors.
- Over 300,000 cumulative prescriptions across 2,000 Korean medical institutions.
- Included in 2026 Korean Society of Hypertension Guidelines as first ring-type cuffless monitor.
The big picture
Sky Labs' clinical validation of its CART monitor represents a significant step in the evolution of chronic cardiovascular disease management. The company's ability to demonstrate utility in challenging patient populations like AF and heart failure patients positions it favorably in the growing market for continuous health monitoring solutions. With over 300,000 prescriptions and inclusion in national guidelines, Sky Labs appears well-positioned to capitalize on increasing demand for wearable medical devices that enable personalized treatment approaches.
What we're watching
- Market Expansion
- Whether Sky Labs can successfully scale its European and global market expansion following clinical validations.
- Regulatory Compliance
- The pace at which CART gains regulatory approvals in key international markets beyond Korea.
- Competitive Positioning
- How Sky Labs differentiates itself against potential entrants in the cuffless blood pressure monitoring space.
Related topics